InvestorsHub Logo
Followers 138
Posts 22891
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Wednesday, 08/20/2014 8:22:30 PM

Wednesday, August 20, 2014 8:22:30 PM

Post# of 2206
Benitec's hepatitis C treatment TT-034

"...In summary, we have shown that complete transduction of hepatocytes with TT-034 in a NHP, at levels that yield 100% inhibition in the replicon models. These doses of the modified vector, which can be delivered by a single injection, were not associated with toxicity in either mice or NHPs. These data justify the progression of this molecule to the clinic for the treatment of chronically infected HCV patients...."

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437581/#__ffn_sectitle

Good luck and GOD bless,

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News